Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinica...( SOUTH SAN FRANCISCO Calif. Feb. 2...),Health
Navigation Links
Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
Date:2/26/2008
SOUTH SAN FRANCISCO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has named Daniel B. Magilavy, M.D. vice president of clinical research. In this newly created position, Dr. Magilavy will be responsible for the direction and oversight of Rigel's clinical research programs in rheumatoid arthritis (RA), and related autoimmune disorders. Rigel's R788, oral syk kinase inhibitor, is expected to enter advanced Phase 2 clinical studies for RA and ITP this year, and also a Phase 2 clinical study in systemic lupus erythematosus. In addition, Rigel's oral JAK3 inhibitor, R348, is currently in a Phase 1 study for the potential treatment of psoriasis and RA.
"Dan comes to Rigel with solid clinical research leadership experience and expertise in the medical subspecialties for which we are developing drugs," said Elliott B. Grossbard, M.D., Rigel's executive vice president and chief medical officer. "I look forward to working with him as we continue to expand our clinical research programs," he added.
Dr. Magilavy most recently served as Senior Medical Director at Genzyme, Inc. He began his career in the biopharmaceutical industry as Director of Medical Research at Biogen, Inc. from 1994-2000. In these positions, Dr. Magilavy interacted with preclinical and clinical research organizations, various regulatory agencies, and was integral to the decision making processes relating to new drug development.
Dr. Magilavy received his M.D. from Ohio State University in 1972 and
was most recently a lecturer in the Department of Pediatrics of Harvard
Medical School. Prior to that he was Associate Professor of Pediatrics and
Immunology, and Director of the Section of Rheumatology
'/>"/>
| SOURCE Rigel Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
2. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
3. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
4. Microsoft Joins Forces with SAP America for Healthcare IT
5. Nationally Recognized Information Technology Veteran and Entrepreneur John Bamberger Joins gloStream, Inc. as Chief Channel Officer
6. John OConnell Joins Finesse Solutions as Vice-President of Sales and Business Development
7. Host Jennifer Love Hewitt Joins SBE, The Abbey and Los Angeles Magazine for The Envelope Please, Benefiting AIDS Project Los Angeles
8. True Orange Joins the True Lemon & True Lime Family
9. Secretary Norman Y. Mineta Joins Lung Cancer Alliance Board of Directors
10. Kelli Pedroia, Wife of Red Sox Dustin Pedroia, Joins Melanoma Foundation of New England to Warn About Tanning for the Prom
11. APA Joins With Give an Hour to Help Military Families
Post Your Comments:
(Date:12/3/2009)... Chiropractic Traffic has gotten in... a very popular marketing tool. $1 gets chiropract...ods. Chiropractic Traffic is even including chiro... (PRWEB) December 3, 2009 -- ...w Email marketing tool. Chiropractic Marketing ex...
(Date:12/3/2009)... SOUTHBRIDGE, Mass., Dec. 3 The ...to treat its first patients, Harrington Hospital a...atients immediately," said Diane Becquart, Directo...proval was granted today by the Massachusetts Depa...lity review of the facility. ,, The opening of...
(Date:12/3/2009)... , WASHINGTON, Dec. 3 /PRNewswire-USNewswire/ ...amendment to the Senate health care bill by a vote...ire abortion coverage, but it also fails to explic...ces Administration (HRSA) could categorize abortio...end coverage for abortion by all private plans. T...
(Date:12/3/2009)..., BEVERLY HILLS, Calif., Dec. 3 C...,s Divine Design Gala and Premier Shopping Event f...ced at 50-70% off regular prices. The event kicks...ay, December 7, 2009, located at 9900 Wilshire Bou...lifornia. Please visit www.divinedesign.org for...
(Date:12/3/2009)...nues for 12 weeks and includes minimally invasive ...c. 3 (HealthDay News) -- Potentially fatal blood c...s previously been thought, a British study finds. ...e risk higher, but that it lasts much longer than ...cal epidemiologist at the University of Oxford and...
Breaking Medicine News(10 mins):Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Americans United For Life: Senate Passes the Pro-Abortion Mikulski Amendment Under the Guise of 'Preventive Care' 2Health News:Christian Audigier Represented at Divine Design for Project Angel Food 2Health News:Blood Clot Threat After Surgery Worse Than Thought 2Health News:Blood Clot Threat After Surgery Worse Than Thought 3[0] New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s[0] Cancer Center at Harrington to Begin Seeing Patients[0] Americans United For Life: Senate Passes the Pro-Abortion Mikulski Amendment Under the Guise of 'Preventive Care'[0] Christian Audigier Represented at Divine Design for Project Angel Food[0] Blood Clot Threat After Surgery Worse Than Thought
... sugar induces abnormalities in immune systems, wh...s in the liver, according to a study of mice // co... in Baltimore.
The study, published in the Oc...ls of a cytokine that reduces NKT cells.
A hi...
...ed by Dr. Martine Roussel of the St. Jude Children...f medulloblastoma, the most common malignant brain...lloblastomas are malignant tumors that are formed ...alled the cerebellum. It may be recalled here that...
...sodes of bilateral muscle weakness with areflexia ...o narcolepsy. Cataplexy is diagnosed based on clin...eveloped recently but their usefulness has been li...have an understanding of the typical features of c...
...nt of bleeding from solid abdominal organs has bee...on and correction of coagulopathy, which has latel... are new and sophisticated methods for the control... drug" that can improve coagulation, reduce bleedi...
...ntroduced a new law by which the consumers using h...f the composition of the drugs, toxicity levels an...// The new directive will provide consumers with l...val about the usage, quality and safety of the her...
... that leads to inflammation of the liver is common...-80 % of abusers are suffering from // the disease...n has generated interest in determining the effect...n and drug abuse. It has now been established from...
Other Medicine News:Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2Health News:Morphine Withdrawal Complicates Hepatitis C Infection in Drug Abusers 2(Date:12/3/2009)...., Dec. 3 ParagonRx, a Delaware-ba...nagement and optimal medication use, will host a f...ft guidance on REMS - Risk Evaluation Mitigation S...ifecycle management. Dr. Gary Slatko, chief medic...risk management programs, will lead the one-hour p...
(Date:12/3/2009)... Texas, Dec. 3 Wound...: WNDM), a rapidly growing provider of specialty m... the Health Industry Representative Association (H... and marketing representative to market the compan...S. ,, HIRA will market and sell Wound Manageme...
(Date:12/3/2009)... Dec. 3 TROY Group, Inc., a World..., announces the addition of the TROY 3015 SecureR...rinting solutions. Based on the HP LaserJet Enterp...) Printers provide a fast 42 page per minute print...bility and enhanced TROY prescription security fea...
Breaking Medicine Technology:Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2Illinois Dermatologists Tee Up for Sun Safety at Two World Class Golf Championships 54613 1Illinois Dermatologists Tee Up for Sun Safety at Two World Class Golf Championships 54613 2Noted Cosmetic Eyelid Specialist B Bruce Myers MD FACS Retains TransMedia Group to Promote His Vision 54611 1Noted Cosmetic Eyelid Specialist B Bruce Myers MD FACS Retains TransMedia Group to Promote His Vision 54611 2Dr Jack P Gunter Offers 3D Imaging for Dallas Texas Plastic Surgery Patients 54609 1Dr Jack P Gunter Offers 3D Imaging for Dallas Texas Plastic Surgery Patients 54609 2Dr Jack P Gunter Offers 3D Imaging for Dallas Texas Plastic Surgery Patients 54609 3Dr Jack P Gunter Offers 3D Imaging for Dallas Texas Plastic Surgery Patients 54609 4[0] Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management[0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up[0] New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone
...re/ -- PARI Pharma will,present in-vivo study resu...ystem as well as lung deposition and pharmacokinet...losporin A formulation in,lung transplant patients... in Belek, Turkey this week. , Continuing their tr...elivery platforms, PARI has created a pulsating si...
..., 2007) - Ambrilia,Biopharma Inc. (TSX:AMB), a bio...cules and peptides to treat infectious diseases an...ing today, during,which the data reported yesterda...and recent developments were highlighted. The,meet...Mr. Frederic,Porte, and a progress report was pres...
Other Medicine Technology:PARI Pharma Presents Study Results of Sinus Delivery and Inhaled,Liposomal Ciclosporin A at European Cystic Fibrosis Conference 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |